Venetoclax (BioDeep_00000858554)
代谢物信息卡片
ABT-199 (GDC-0199)
化学式: C45H50ClN7O7S (867.318078)
中文名称: 维奈克拉
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C
InChI: InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)
描述信息
C274 - Antineoplastic Agent > C129839 - Apoptotic Pathway-targeting Antineoplastic Agent > C192025 - Bcl-2 Family Protein Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C159200 - BCL-2 Inhibitor
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents
D000970 - Antineoplastic Agents
同义名列表
2 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:133021
- KEGGdrug: D10679
- PubChem: 49846579
- DrugBank: DB11581
- ChEMBL: CHEMBL3137309
- CAS: 1257044-40-8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Ziyi Hao, Yingying Fei, Juan Chen, Sailan Huang, Li Wang, Youhuan Yu, Meiru Bian, Yejun Si, Xingxia Zhang, Xiaotian Yang, Bing Zhang, Yan Wan, Yanming Zhang, Guoqiang Lin. Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center.
Hematology (Amsterdam, Netherlands).
2024 Dec; 29(1):2344998. doi:
10.1080/16078454.2024.2344998. [PMID: 38666535] - Cuiping Ma, Haiyan Lang, Yuhan Chen, Lu Yang, Chong Wang, Lizhen Han, Xinyi Chen, Wei Ma. Azacitidine combined with venetoclax alleviates AML-MR with TP53 mutation in SDS: a case report and literature review.
Anti-cancer drugs.
2024 Jul; 35(6):548-555. doi:
10.1097/cad.0000000000001594. [PMID: 38502829] - Sichun Xiang, Rongbin Shen, Jingjing Xiang, Ni Zhu, Jianyou Gu, Jianping Shen, Yu Zhang, Hangping Ge. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Bruton's tyrosine kinase inhibitors (BTKis) single and its combination therapy.
Expert opinion on drug safety.
2024 May; 23(5):627-636. doi:
10.1080/14740338.2024.2327507. [PMID: 38456691] - Yihan Zhao, Shiqing Jiang, Yujun Tang, Lin Zhao. Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review.
International journal of hematology.
2023 Oct; 118(4):483-488. doi:
10.1007/s12185-023-03623-w. [PMID: 37269505] - Xia Jiang, Ye Lin, Mengting Zhao, Youhong Li, Peipei Ye, Renzhi Pei, Ying Lu, Lei Jiang. Platycodin D induces apoptotic cell death through PI3K/AKT and MAPK/ERK pathways and synergizes with venetoclax in acute myeloid leukemia.
European journal of pharmacology.
2023 Aug; 956(?):175957. doi:
10.1016/j.ejphar.2023.175957. [PMID: 37541375] - Florian Daressy, Line Séguy, Loëtitia Favre, Sophie Corvaisier, Cécile Apel, Anne-Claire Groo, Marc Litaudon, Vincent Dumontet, Aurélie Malzert-Fréon, Sandy Desrat, Fanny Roussi, Aude Robert, Joëlle Wiels. NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2022 Oct; 154(?):113546. doi:
10.1016/j.biopha.2022.113546. [PMID: 35988426] - Chih-Chieh Chen, Zhi-Jie Zhuang, Chia-Wei Wu, Yi-Ling Tan, Chen-Hsiu Huang, Chia-Yi Hsu, Eing-Mei Tsai, Tsung-Hua Hsieh. Venetoclax Decreases the Expression of the Spike Protein through Amino Acids Q493 and S494 in SARS-CoV-2.
Cells.
2022 06; 11(12):. doi:
10.3390/cells11121924. [PMID: 35741053] - Debora Soncini, Claudia Martinuzzi, Pamela Becherini, Elisa Gelli, Samantha Ruberti, Katia Todoerti, Luca Mastracci, Paola Contini, Antonia Cagnetta, Antonella Laudisi, Fabio Guolo, Paola Minetto, Maurizio Miglino, Sara Aquino, Riccardo Varaldo, Daniele Reverberi, Matteo Formica, Mario Passalacqua, Alessio Nencioni, Antonino Neri, Mehmet K Samur, Nikhil C Munshi, Mariateresa Fulciniti, Roberto M Lemoli, Michele Cea. Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment.
Haematologica.
2022 06; 107(6):1410-1426. doi:
10.3324/haematol.2021.279276. [PMID: 34670358] - Sankalp Arora, Carl Zainaldin, Srilakshmi Bathini, Udita Gupta, Sarah Worth, Kimo Bachiashvili, Ravi Bhatia, Kelly Godby, Omer Jamy, Sravanti Rangaraju, Barry Diamond, Josh D Oliver, Donna Salzman, Antonio Di Stasi, Pankit Vachhani. Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia.
Leukemia research.
2022 06; 117(?):106844. doi:
10.1016/j.leukres.2022.106844. [PMID: 35487134] - Anna Candoni, Chiara Callegari, Maria Elena Zannier, Renato Fanin. Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax.
Blood advances.
2022 05; 6(10):3068-3071. doi:
10.1182/bloodadvances.2021006949. [PMID: 35108726] - Deanna Brackman, Doerthe Eckert, Rajeev Menon, Ahmed Hamed Salem, Jalaja Potluri, B Douglas Smith, Andrew H Wei, John Hayslip, Dale Miles, Sven Mensing, Sathej Gopalakrishnan, Jiuhong Zha. Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.
Hematological oncology.
2022 Apr; 40(2):269-279. doi:
10.1002/hon.2964. [PMID: 35043428] - Tina Roy, Joseph B An, Kimberly Doucette, Aimee M Chappell, David H Vesole. Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression.
Leukemia & lymphoma.
2022 03; 63(3):759-761. doi:
10.1080/10428194.2021.2010065. [PMID: 35076333] - Xi Yang, Chen Mei, Xiaoying He, Lingjuan He, Xiaoyang Lu, Hongyan Tong, Yan Lou. Quantification of Venetoclax for Therapeutic Drug Monitoring in Chinese Acute Myeloid Leukemia Patients by a Validated UPLC-MS/MS Method.
Molecules (Basel, Switzerland).
2022 Feb; 27(5):. doi:
10.3390/molecules27051607. [PMID: 35268708] - Amr Alaarg, Rajeev Menon, David Rizzo, Yemin Liu, Jeffrey Bien, Tricia Elkinton, Timothy Grieme, Lutz R Asmus, Ahmed Hamed Salem. A microdosing framework for absolute bioavailability assessment of poorly soluble drugs: A case study on cold-labeled venetoclax, from chemistry to the clinic.
Clinical and translational science.
2022 01; 15(1):244-254. doi:
10.1111/cts.13144. [PMID: 34416076] - Niklas J Koehl, Laura J Henze, René Holm, Martin Kuentz, John J Keating, Thomas De Vijlder, Andreas Marx, Brendan T Griffin. Lipophilic Salts and Lipid-Based Formulations for Bridging the Food Effect Gap of Venetoclax.
Journal of pharmaceutical sciences.
2022 01; 111(1):164-174. doi:
10.1016/j.xphs.2021.09.008. [PMID: 34516990] - Virág Réka Szita, Gábor Mikala, András Kozma, János Fábián, Apor Hardi, Hussain Alizadeh, Péter Rajnics, László Rejtő, Tamás Szendrei, László Váróczy, Zsolt Nagy, Árpád Illés, István Vályi-Nagy, Tamás Masszi, Gergely Varga. Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers.
Pathology oncology research : POR.
2022; 28(?):1610276. doi:
10.3389/pore.2022.1610276. [PMID: 35295611] - Anuradha Reddy, Tarang Jadav, Amit Kumar Sahu, Pinaki Sengupta. LC-MS/MS bioanalytical method for quantification of binimetinib and venetoclax, and their pharmacokinetic interaction.
Bioanalysis.
2022 Jan; 14(2):75-86. doi:
10.4155/bio-2021-0207. [PMID: 34841894] - Akihiro Kitadate, Toshiki Terao, Kentaro Narita, Sho Ikeda, Yuto Takahashi, Takafumi Tsushima, Daisuke Miura, Masami Takeuchi, Naoto Takahashi, Kosei Matsue. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
Cancer science.
2021 Sep; 112(9):3645-3654. doi:
10.1111/cas.15073. [PMID: 34288263] - N Kutsch, K Fischer. [66/m-with chronic lymphocytic leukemia and acute renal failure under treatment with obinutuzumab and venetoclax : Preparation for the medical specialist examination: part 54].
Der Internist.
2021 Sep; 62(Suppl 4):372-374. doi:
10.1007/s00108-021-01061-6. [PMID: 34160636] - Hareth Nahi, Muhammad Kashif, Monika Klimkowska, Maria Karvouni, Ann Wallblom, Charlotte Gran, Julia Hauenstein, Nicolai Frengen, Charlotte Gustafsson, Gabriel Afram, Katarina Uttervall, Johan Lund, Robert Månsson, Arnika K Wagner, Evren Alici. Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14).
American journal of hematology.
2021 08; 96(8):925-933. doi:
10.1002/ajh.26207. [PMID: 33901326] - Yan Li, Wenjie Fan, Qineng Gong, Jie Tian, Mi Zhou, Qing Li, Laura B Uwituze, Zhichao Zhang, Ran Hong, Renxiao Wang. Structure-Based Optimization of 3-Phenyl-N-(2-(3-phenylureido)ethyl)thiophene-2-sulfonamide Derivatives as Selective Mcl-1 Inhibitors.
Journal of medicinal chemistry.
2021 07; 64(14):10260-10285. doi:
10.1021/acs.jmedchem.1c00690. [PMID: 34228434] - Ashkan Emadi, Bandish Kapadia, Dominique Bollino, Binny Bhandary, Maria R Baer, Sandrine Niyongere, Erin T Strovel, Hannah Kaizer, Elizabeth Chang, Eun Yong Choi, Xinrong Ma, Kayla M Tighe, Brandon Carter-Cooper, Blake S Moses, Curt I Civin, Anup Mahurkar, Amol C Shetty, Ronald B Gartenhaus, Farin Kamangar, Rena G Lapidus. Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia.
Leukemia.
2021 07; 35(7):1907-1924. doi:
10.1038/s41375-020-01080-6. [PMID: 33199836] - Laura J Henze, Niklas J Koehl, Joseph P O'Shea, René Holm, Maria Vertzoni, Brendan T Griffin. Combining species specific in vitro & in silico models to predict in vivo food effect in a preclinical stage - case study of Venetoclax.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2021 Jul; 162(?):105840. doi:
10.1016/j.ejps.2021.105840. [PMID: 33845120] - Ana Colado, Esteban Enrique Elías, Valeria Judith Sarapura Martínez, Gregorio Cordini, Pablo Morande, Fernando Bezares, Mirta Giordano, Romina Gamberale, Mercedes Borge. Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia.
Scientific reports.
2021 06; 11(1):12926. doi:
10.1038/s41598-021-92412-8. [PMID: 34155276] - Niklas J Koehl, Laura J Henze, Harriet Bennett-Lenane, Waleed Faisal, Daniel J Price, René Holm, Martin Kuentz, Brendan T Griffin. In Silico, In Vitro, and In Vivo Evaluation of Precipitation Inhibitors in Supersaturated Lipid-Based Formulations of Venetoclax.
Molecular pharmaceutics.
2021 06; 18(6):2174-2188. doi:
10.1021/acs.molpharmaceut.0c00645. [PMID: 33890794] - Jayaprakasam Bolleddula, Alice Ke, Hua Yang, Chandra Prakash. PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction.
CPT: pharmacometrics & systems pharmacology.
2021 06; 10(6):577-588. doi:
10.1002/psp4.12619. [PMID: 33822485] - Neeta Bala Tannan, Mandana T Manzari, Laurie Herviou, Mariana Da Silva Ferreira, Connor Hagen, Hiroto Kiguchi, Katia Manova-Todorova, Venkatraman Seshan, Elisa de Stanchina, Daniel A Heller, Anas Younes. Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition.
Blood.
2021 04; 137(15):2057-2069. doi:
10.1182/blood.2020008017. [PMID: 33067607] - Mohammed Isaac Abu Zaanona, Priyank Patel. Plasma cell leukaemia with t(11;14) not responsive to venetoclax.
BMJ case reports.
2021 Jan; 14(1):. doi:
10.1136/bcr-2020-238641. [PMID: 33495184] - Michael Asger Andersen, Rebecca Valentin, Lene Dissing Sjö, Line Borgwardt, Kjeld Schmiegelow, Mette Klarskov Andersen, Rasmus L Marvig, Christina Westmose Yde, Carsten Utoft Niemann. Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma.
Acta oncologica (Stockholm, Sweden).
2020 Dec; 59(12):1547-1551. doi:
10.1080/0284186x.2020.1821913. [PMID: 32970500] - Irit Avivi, Moshe E Gatt, Efrat Luttwak, Hila Magen, Najib Dally, Yael C Cohen, Noam Benyamini, Noa Lavi. The impact of anti-bacterial prophylaxis on the outcome of patients treated with venetoclax-based regimens for relapsed/refractory plasma cell dyscrasias: Real-life data.
Leukemia research.
2020 10; 97(?):106429. doi:
10.1016/j.leukres.2020.106429. [PMID: 32861018] - Rajshekhar Chakraborty, Suzanne Lentzsch. Emerging drugs for the treatment of light chain amyloidosis.
Expert opinion on emerging drugs.
2020 09; 25(3):299-317. doi:
10.1080/14728214.2020.1803829. [PMID: 32731778] - Eric D Eisenmann, Yan Jin, Robert H Weber, Alex Sparreboom, Sharyn D Baker. Development and validation of a sensitive UHPLC-MS/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2020 Sep; 1152(?):122176. doi:
10.1016/j.jchromb.2020.122176. [PMID: 32534260] - Moritz Fürstenau, Petra Langerbeins, Nisha De Silva, Anna Maria Fink, Sandra Robrecht, Julia von Tresckow, Florian Simon, Karin Hohloch, Jolanda Droogendijk, Marjolein van der Klift, Ellen van der Spek, Thomas Illmer, Björn Schöttker, Kirsten Fischer, Clemens M Wendtner, Eugen Tausch, Stephan Stilgenbauer, Carsten U Niemann, Michael Gregor, Arnon P Kater, Michael Hallek, Barbara Eichhorst. COVID-19 among fit patients with CLL treated with venetoclax-based combinations.
Leukemia.
2020 08; 34(8):2225-2229. doi:
10.1038/s41375-020-0941-7. [PMID: 32601378] - Pui-Lun Yip, June S M Lau, Ching-Pong Lam. Venetoclax monotherapy induced rapid and sustained response in a frail patient with refractory AL amyloidosis: Less is more?.
International journal of hematology.
2020 Aug; 112(2):234-237. doi:
10.1007/s12185-020-02857-2. [PMID: 32207051] - Nelson Leung, David Dingli. Venetoclax in a Patient With Light Chain Deposition Disease Secondary to MGRS That Progressed After Kidney Transplantation.
Clinical lymphoma, myeloma & leukemia.
2020 08; 20(8):e488-e491. doi:
10.1016/j.clml.2020.03.013. [PMID: 32466980] - Siobhan V Glavey, Lyndsey Flanagan, Rachel Bleach, Claire Kelly, John Quinn, Tríona Ní Chonghaile, Philip Murphy. Secondary plasma cell leukaemia treated with single agent venetoclax.
British journal of haematology.
2020 08; 190(4):e242-e245. doi:
10.1111/bjh.16858. [PMID: 32525557] - Yuan-Fei Shi, Long Liu, Ling-Li He, Jing Ye, Zhi-Juan Lin, De-Lin Yuan, Man-Man Deng, Zhi-Hong Fang, Bing Z Carter, Bing Xu. Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway.
Cell death & disease.
2020 07; 11(7):555. doi:
10.1038/s41419-020-02762-w. [PMID: 32699295] - Allison Kupsh, Justin Arnall, Peter Voorhees. A successful case of venetoclax-based therapy in relapsed/refractory secondary plasma cell leukemia.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2020 Jul; 26(5):1274-1278. doi:
10.1177/1078155219895072. [PMID: 31865846] - Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Caleb A Class, Koji Sasaki, Farhad Ravandi, Jorge E Cortes, Naval Daver, Koichi Takahashi, Nicholas J Short, Courtney D DiNardo, Elias Jabbour, Gautam Borthakur, Kiran Naqvi, Ghayas C Issa, Marina Konopleva, Joseph D Khoury, Mark Routbort, Sherry Pierce, Kim-Anh Do, Carlos Bueso-Ramos, Keyur Patel, Hagop Kantarjian, Guillermo Garcia-Manero, Tapan M Kadia. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
American journal of hematology.
2020 06; 95(6):612-622. doi:
10.1002/ajh.25769. [PMID: 32112433] - Qing Li, Ran An, Yaochun Xu, Mi Zhou, Yan Li, Chun Guo, Renxiao Wang. Synthesis of (1,3,4-thiadiazol-2-yl)-acrylamide derivatives as potential antitumor agents against acute leukemia cells.
Bioorganic & medicinal chemistry letters.
2020 05; 30(10):127114. doi:
10.1016/j.bmcl.2020.127114. [PMID: 32209294] - Cecilia Bonolo de Campos, Nathalie Meurice, Joachim L Petit, Alysia N Polito, Yuan Xiao Zhu, Panwen Wang, Laura A Bruins, Xuewei Wang, Ilsel D Lopez Armenta, Susie A Darvish, Greg J Ahmann, Kimberly J Henderson, Shulan Tian, Jonas J Kruse, William M Stewart, Jeremy T Larsen, Craig B Reeder, David Dingli, Prashant Kapoor, Shaji K Kumar, Rafael Fonseca, P Leif Bergsagel, Esteban Braggio, A Keith Stewart. 'Direct to Drug' screening as a precision medicine tool in multiple myeloma.
Blood cancer journal.
2020 05; 10(5):54. doi:
10.1038/s41408-020-0320-7. [PMID: 32393731] - Khadega A Abuelgasim, Noha Alherz, Ayman Alhejazi, Moussab Damlaj. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
Journal of medical case reports.
2020 Apr; 14(1):54. doi:
10.1186/s13256-020-02376-y. [PMID: 32321588] - Ahmed Nader, Mukul Minocha, Ahmed A Othman. Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus.
Clinical pharmacokinetics.
2020 03; 59(3):335-347. doi:
10.1007/s40262-019-00818-5. [PMID: 31541431] - Sos Nalghranyan, Amrit P Singh, Carolina Schinke. The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia.
American journal of hematology.
2020 02; 95(2):E34-E35. doi:
10.1002/ajh.25676. [PMID: 31709578] - Francesco Paolo Tambaro, William G Wierda. Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations.
The Lancet. Haematology.
2020 Feb; 7(2):e168-e176. doi:
10.1016/s2352-3026(19)30253-4. [PMID: 32004486] - Charlotte Gran, Johanna Borg Bruchfeld, Fredrik Ellin, Hareth Nahi. Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis.
Acta haematologica.
2020; 143(5):500-503. doi:
10.1159/000504355. [PMID: 31896106] - Guido Ghilardi, Georg Stussi, Luca Mazzucchelli, Christoph Röcken, Davide Rossi, Bernhard Gerber. Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14).
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
2019 Sep; 26(3):173-174. doi:
10.1080/13506129.2019.1615428. [PMID: 31232114] - Ahmed Hamed Salem, Nimita Dave, Thomas Marbury, Beibei Hu, Dale Miles, Suresh K Agarwal, Orlando F Bueno, Rajeev M Menon. Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment.
Clinical pharmacokinetics.
2019 08; 58(8):1091-1100. doi:
10.1007/s40262-019-00746-4. [PMID: 30949874] - Rong Chen, Mingzhao Zhu, Rajan R Chaudhari, Omar Robles, Yuling Chen, Wesley Skillern, Qun Qin, William G Wierda, Shuxing Zhang, Kenneth G Hull, Daniel Romo, William Plunkett. Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia.
Leukemia.
2019 07; 33(7):1663-1674. doi:
10.1038/s41375-018-0364-x. [PMID: 30700841] - Jacob D Soumerai, Ai Ni, Mohamed Darif, Anil Londhe, Guan Xing, Yong Mun, Neil E Kay, Tait D Shanafelt, Kari G Rabe, John C Byrd, Asher A Chanan-Khan, Richard R Furman, Peter Hillmen, Jeffrey Jones, John F Seymour, Jeffrey P Sharman, Lucille Ferrante, Mehrdad Mobasher, Thomas Stark, Vijay Reddy, Lyndah K Dreiling, Pankaj Bhargava, Angela Howes, Danelle F James, Andrew D Zelenetz. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
The Lancet. Haematology.
2019 Jul; 6(7):e366-e374. doi:
10.1016/s2352-3026(19)30085-7. [PMID: 31109827] - Fangbing Liu, Tristan Knight, Yongwei Su, Holly Edwards, Guan Wang, Yue Wang, Jeffrey W Taub, Hai Lin, Liwei Sun, Yubin Ge. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Targeted oncology.
2019 06; 14(3):351-364. doi:
10.1007/s11523-019-00638-4. [PMID: 31115744] - Bo Zhang, Linling Wang, Qi Zhang, Youyou Yan, Hong Jiang, Runlei Hu, Xinglu Zhou, Xingguo Liu, Jianguo Feng, Nengming Lin. The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling.
Molecular oncology.
2019 04; 13(4):946-958. doi:
10.1002/1878-0261.12454. [PMID: 30663221] - Sheau W Lok, James R Whittle, François Vaillant, Charis E Teh, Louisa L Lo, Antonia N Policheni, Alice R T Bergin, Jayesh Desai, Sarah Ftouni, Luke C Gandolfo, Danny Liew, He K Liu, G Bruce Mann, Kate Moodie, Anand Murugasu, Bhupinder Pal, Andrew W Roberts, Mark A Rosenthal, Kylie Shackleton, Maria João Silva, Zhen R Siow, Gordon K Smyth, Leanne Taylor, Avraham Travers, Belinda Yeo, Miriam M Yeung, Andjelija Zivanovic Bujak, Sarah-Jane Dawson, Daniel H D Gray, Jane E Visvader, Geoffrey J Lindeman. A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer.
Cancer discovery.
2019 03; 9(3):354-369. doi:
10.1158/2159-8290.cd-18-1151. [PMID: 30518523] - Yi-Chen Chen, Jane R Kenny, Matthew Wright, Cornelis E C A Hop, Zhengyin Yan. Improving Confidence in the Determination of Free Fraction for Highly Bound Drugs Using Bidirectional Equilibrium Dialysis.
Journal of pharmaceutical sciences.
2019 03; 108(3):1296-1302. doi:
10.1016/j.xphs.2018.10.011. [PMID: 30326208] - Rayelle Itoua Maïga, Regina Cencic, Jennifer Chu, Daniel D Waller, Lauren E Brown, William G Devine, Wenhan Zhang, Michael Sebag, John A Porco, Jerry Pelletier. Oxo-aglaiastatin-Mediated Inhibition of Translation Initiation.
Scientific reports.
2019 02; 9(1):1265. doi:
10.1038/s41598-018-37666-5. [PMID: 30718665] - Tomas Jelinek, Jana Mihalyova, Michal Kascak, Juraj Duras, Tereza Popkova, Katerina Benkova, Petra Richterova, Hana Plonkova, Jana Zuchnicka, Lucie Broskevicova, Lucie Huvarova, Lucie Cerna, Katerina Growkova, Michal Simicek, Martin Havel, Jaromir Gumulec, Milan Navratil, Zdenek Koristek, Bruno Paiva, Roman Hajek. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).
American journal of hematology.
2019 01; 94(1):E35-E37. doi:
10.1002/ajh.25331. [PMID: 30370955] - Courtney L Jones, Brett M Stevens, Angelo D'Alessandro, Julie A Reisz, Rachel Culp-Hill, Travis Nemkov, Shanshan Pei, Nabilah Khan, Biniam Adane, Haobin Ye, Anna Krug, Dominik Reinhold, Clayton Smith, James DeGregori, Daniel A Pollyea, Craig T Jordan. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells.
Cancer cell.
2018 11; 34(5):724-740.e4. doi:
10.1016/j.ccell.2018.10.005. [PMID: 30423294] - Mukul Minocha, Jiewei Zeng, Jeroen K Medema, Ahmed A Othman. Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus.
Clinical pharmacokinetics.
2018 09; 57(9):1185-1198. doi:
10.1007/s40262-017-0625-2. [PMID: 29333561] - Manoj S Chiney, Rajeev M Menon, Orlando F Bueno, Bo Tong, Ahmed Hamed Salem. Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin.
Xenobiotica; the fate of foreign compounds in biological systems.
2018 Sep; 48(9):904-910. doi:
10.1080/00498254.2017.1381779. [PMID: 29027832] - Cyrille Touzeau, Paulo Maciag, Martine Amiot, Philippe Moreau. Targeting Bcl-2 for the treatment of multiple myeloma.
Leukemia.
2018 09; 32(9):1899-1907. doi:
10.1038/s41375-018-0223-9. [PMID: 30076373] - Dongsheng Zhu, Haijun Guo, Yu Chang, Yun Ni, Lin Li, Zhi-Min Zhang, Piliang Hao, Yong Xu, Ke Ding, Zhengqiu Li. Cell- and Tissue-Based Proteome Profiling and Dual Imaging of Apoptosis Markers with Probes Derived from Venetoclax and Idasanutlin.
Angewandte Chemie (International ed. in English).
2018 07; 57(30):9284-9289. doi:
10.1002/anie.201802003. [PMID: 29768700] - V K Patel, B Lamothe, M L Ayres, J Gay, J P Cheung, K Balakrishnan, C Ivan, J Morse, M Nelson, M J Keating, W G Wierda, J R Marszalek, V Gandhi. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
Leukemia.
2018 04; 32(4):920-930. doi:
10.1038/leu.2017.321. [PMID: 29099493] - Wilson I Gonsalves, Francis K Buadi, Shaji K Kumar. Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14).
European journal of haematology.
2018 Feb; 100(2):215-217. doi:
10.1111/ejh.12986. [PMID: 29064593] - Arian Emami Riedmaier, David J Lindley, Jeffrey A Hall, Steven Castleberry, Russell T Slade, Patricia Stuart, Robert A Carr, Thomas B Borchardt, Daniel A J Bow, Marjoleen Nijsen. Mechanistic Physiologically Based Pharmacokinetic Modeling of the Dissolution and Food Effect of a Biopharmaceutics Classification System IV Compound-The Venetoclax Story.
Journal of pharmaceutical sciences.
2018 01; 107(1):495-502. doi:
10.1016/j.xphs.2017.09.027. [PMID: 28993217] - Kevin J Freise, Aksana K Jones, Rajeev M Menon, Maria E Verdugo, Rod A Humerickhouse, Walid M Awni, Ahmed Hamed Salem. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Hematological oncology.
2017 Dec; 35(4):679-684. doi:
10.1002/hon.2373. [PMID: 27982454] - Ahmed Hamed Salem, Martin Dunbar, Suresh K Agarwal. Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia.
Anti-cancer drugs.
2017 09; 28(8):911-914. doi:
10.1097/cad.0000000000000522. [PMID: 28562380] - Zhong Zheng, Peng-Peng Xu, Li Wang, Hui-Jin Zhao, Xiang-Qin Weng, Hui-Juan Zhong, Bin Qu, Jie Xiong, Yan Zhao, Xue-Feng Wang, Anne Janin, Wei-Li Zhao. MiR21 sensitized B-lymphoma cells to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cells.
Journal of experimental & clinical cancer research : CR.
2017 06; 36(1):82. doi:
10.1186/s13046-017-0551-z. [PMID: 28637496] - Ahmed Hamed Salem, Suresh K Agarwal, Martin Dunbar, Sari L Heitner Enschede, Rod A Humerickhouse, Shekman L Wong. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
Journal of clinical pharmacology.
2017 04; 57(4):484-492. doi:
10.1002/jcph.821. [PMID: 27558232] - Suresh K Agarwal, Ahmed Hamed Salem, Alexey V Danilov, Beibei Hu, Soham Puvvada, Martin Gutierrez, David Chien, Lionel D Lewis, Shekman L Wong. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
British journal of clinical pharmacology.
2017 04; 83(4):846-854. doi:
10.1111/bcp.13175. [PMID: 27859472] - Hong Liu, Melissa J Michmerhuizen, Yanbin Lao, Katty Wan, Ahmed Hamed Salem, James Sawicki, Michael Serby, Srirajan Vaidyanathan, Shekman L Wong, Suresh Agarwal, Martin Dunbar, Jens Sydor, Sonia M de Morais, Anthony J Lee. Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites.
Drug metabolism and disposition: the biological fate of chemicals.
2017 03; 45(3):294-305. doi:
10.1124/dmd.116.071613. [PMID: 27993930] - Ahmed Hamed Salem, Beibei Hu, Kevin J Freise, Suresh K Agarwal, Dilraj S Sidhu, Shekman L Wong. Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.
Clinical drug investigation.
2017 Mar; 37(3):303-309. doi:
10.1007/s40261-016-0485-9. [PMID: 27910036] - Suresh K Agarwal, Courtney D DiNardo, Jalaja Potluri, Martin Dunbar, Hagop M Kantarjian, Rod A Humerickhouse, Shekman L Wong, Rajeev M Menon, Marina Y Konopleva, Ahmed Hamed Salem. Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments.
Clinical therapeutics.
2017 Feb; 39(2):359-367. doi:
10.1016/j.clinthera.2017.01.003. [PMID: 28161120] - Victor Peperzak, Erik Slinger, Johanna Ter Burg, Eric Eldering. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling.
Cell death and differentiation.
2017 01; 24(1):111-119. doi:
10.1038/cdd.2016.105. [PMID: 27689871] - Kichul Ko, Jianing Wang, Stuart Perper, Yulei Jiang, Denisse Yanez, Natalya Kaverina, Junting Ai, Vladimir M Liarski, Anthony Chang, Yahui Peng, Li Lan, Susan Westmoreland, Lisa Olson, Maryellen L Giger, Li Chun Wang, Marcus R Clark. Bcl-2 as a Therapeutic Target in Human Tubulointerstitial Inflammation.
Arthritis & rheumatology (Hoboken, N.J.).
2016 11; 68(11):2740-2751. doi:
10.1002/art.39744. [PMID: 27159593] - Kevin J Freise, Martin Dunbar, Aksana K Jones, David Hoffman, Sari L Heitner Enschede, Shekman Wong, Ahmed Hamed Salem. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.
Cancer chemotherapy and pharmacology.
2016 10; 78(4):847-53. doi:
10.1007/s00280-016-3144-1. [PMID: 27586967] - Aksana K Jones, Kevin J Freise, Suresh K Agarwal, Rod A Humerickhouse, Shekman L Wong, Ahmed Hamed Salem. Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis.
The AAPS journal.
2016 09; 18(5):1192-1202. doi:
10.1208/s12248-016-9927-9. [PMID: 27233802] - R Bajpai, S M Matulis, C Wei, A K Nooka, H E Von Hollen, S Lonial, L H Boise, M Shanmugam. Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax.
Oncogene.
2016 07; 35(30):3955-64. doi:
10.1038/onc.2015.464. [PMID: 26640142] - C Touzeau, J Ryan, J Guerriero, P Moreau, T N Chonghaile, S Le Gouill, P Richardson, K Anderson, M Amiot, A Letai. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics.
Leukemia.
2016 Mar; 30(3):761-4. doi:
10.1038/leu.2015.184. [PMID: 26174630]